Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1254-1259

  Del Rowe, John ^a   Scott, C ^a   Werner Wasik, M ^a   Bahary, J P ^a   Curran, W J ^a   Urtasun, R C ^a   Fisher, B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIRAPAZAMINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; OXYGENATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SINGLE BLIND PROCEDURE;

EID: 0034117277     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1254     Document Type: Article

References (25)

1. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
2. Chang CH, Horton J, Schoenfeld D, et al: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997-1007, 1983
3. Denekamp J, Fowler JF, Dische S: The proportion of hypoxic cells in a human tumor. Int J Radiat Oncol Biol Phys 2:1227-1228, 1977
4. Moulder JE, Rockwell S: Tumor hypoxia its impact on cancer therapy. Cancer Metastasis Rev 4:313-341, 1987
5. Stemann DW: Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10:1585-1594, 1984
6. Brown JM, Hall EJ, Hirst DG, et al: Chemical modification of radiation and chemotherapy. Am J Clin Oncol 11:288-303, 1988
7. Gray LH, Conger AD, Ebert M, et al: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953
8. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
9. Hall EJ: Radiobiology for the Radiologist (ed 3). Philadelphia, PA, JB Lippincott, pp 137-160, 1988
10. Henk JM: Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: A rationale for hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 12:1339-1341, 1986
11. Dische S, Anderson PJ, Sealy R, et al: Carcinoma of the cervix-anemia, radiotherapy and hyperbaric oxygen. Br J Radiol 56:251-255, 1983
12. Schmitt G, Wambersie A: Review of the clinical results of fast neutron therapy Radiother Oncol 17:47-56, 1990
13. Laramore GE: Neutron radiotherapy for high grade gliomas: The search for the elusive therapeutic window. Int J Radiat Oncol Biol Phys 19:493-495, 1990
14. Halpern J, Maor MH, Hussey D: Locally advanced breast cancer treated with neutron beams: Long term follow up in 28 patients Int J Radiat Oncol Biol Phys 18:825-831, 1990
15. Schmitt G, Pape H, Zamboglou N: Long term results of neutron and neutron boost irradiation of soft tissue sarcomas. Strahlenther Onkol 166:61-62, 1990
16. Adams GE, Cooke MS: Electron-affinic sensitization I. A structural basis for chemical radiosensitzers in bacteria Int J Radiat Biol 15:457-471, 1969
17. Overgaard J, Hansen HS, Jorgensen K, et al: Primary radiotherapy of larynx and pharynx carcinoma: An analysis of some factors influencing local control and survival patients. Int J Radiat Oncol Biol Phys 12:515-521, 1986
18. Urtasun RC, Chapman JD, Feldstein ML, et al: Peripheral neuropathy related to misonidazole: Incidence and pathology. Br J Cancer 37:271-273, 1987 (suppl 3)
19. Saunders MI, Dische S, Anderson P, et al: The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer 37:268-270, 1987(suppl 3)
20. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48:775-778, 1988
21. Zeman EM, Brown, JM Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-42, 1986
22. Brown JM, Lemmon MJ: SR 4233, a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol 20: 151-156, 1991 (Suppl)
23. Curran WJ, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993
24. Shaw E, Scott C, Souhami L, et al: Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of Radiation Therapy Oncology Group Protocol (90.05). Int J Radiat Oncol Biol Phys 34:647-654, 1996
25. Brookmeyer R, Crawley J: A confidence interval for median survival. Biometrics 38:29-41, 1982